adequan im 500 mg/5ml inj. opl. i.m. amp.
novartis consumer health b.v. - glycosaminolycanpolysulfaat 100 mg/ml - oplossing voor injectie - 500 mg/5ml - glycosaminolycanpolysulfaat 100 mg/ml - glucosaminoglycan polysulfate - paard
voltaflex glucosamine 625 mg, filmomhulde tabletten
glaxosmithkline consumer healthcare b.v. van asch van wijckstraat 55g 3811 lp amersfoort - glucosaminehydrochloride samenstelling overeenkomend met ; glucosamine - filmomhulde tablet - cellulose, microkristallijn (e 460) ; chinolinegeel aluminiumlak (e 104) ; crospovidon (e 1202) ; ijzeroxide geel (e 172) ; lecithine, soya (e 322) ; macrogol 3000 ; magnesiumstearaat (e 470b) ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; povidon k 30 (e 1201) ; talk (e 553 b) ; titaandioxide (e 171) ; tricalciumfosfaat ; zonnegeel fcf aluminiumlak (e 110), - glucosamine
afamcivir 500 mg, filmomhulde tabletten
glaxosmithkline consumer healthcare b.v. - famciclovir; - filmomhulde tablet - famciclovir
prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - influenza-virus oppervlakte-antigenen (hemagglutinine en neuraminidase) van stam a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaccins - actieve immunisatie tegen het h5n1-subtype van influenza a-virus. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.
icandra (previously vildagliptin / metformin hydrochloride novartis)
novartis europharm limited - vildagliptin, metformine hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 en 5. 1 voor de beschikbare gegevens over verschillende combinaties).
lamisil dermgel 1%, gel
glaxosmithkline consumer healthcare b.v. van asch van wijckstraat 55g 3811 lp amersfoort - terbinafine 10 mg/g - gel - benzylalcohol (e 1519) 5 mg/g ; butylhydroxytolueen (e 321) ; carbomeer 974p ; ethanol 100 mg/g ; isopropylmyristaat ; natriumhydroxide (e 524) ; polysorbaat 20 (e 432) ; sorbitanmonolauraat (e 493) ; water, gezuiverd, - terbinafine
lamisil once 1%, oplossing voor cutaan gebruik 10 mg/g
glaxosmithkline consumer healthcare b.v. van asch van wijckstraat 55g 3811 lp amersfoort - terbinafinehydrochloride samenstelling overeenkomend met ; ; terbinafine 10 mg/g - oplossing voor cutaan gebruik - copolymer of isobutylmethacrylate\t-octylacrylamide\acrylic acid (ri) ; ethanol 96 % ; hyprolose (e 463) ; triglyceriden middellange keten, - terbinafine
otrivin duo xylometazolinehydrochloride & ipratropiumbromide, 0,5/0,6 mg/ml, neusspray, oplossing
dr. fisher farma b.v. - ipratropiumbromide 0-water samenstelling overeenkomend met; ipratropium; xylometazolinehydrochloride samenstelling overeenkomend met; xylometazoline; - neusspray, oplossing - xylometazoline
otrivin xylometazolinehcl 1 mg/ml neusspray, oplossing
dr. fisher farma b.v. - xylometazolinehydrochloride samenstelling overeenkomend met; xylometazoline; - neusspray, oplossing - xylometazoline
venoruton tabletten 500
dr. fisher farma b.v. - hydroxyethylrutosiden; - tablet - rutoside, combinations